Document Detail


No long-term effects of hormonal therapy preceding brachytherapy on urinary function and health-related quality of life among prostate cancer patients.
MedLine Citation:
PMID:  20869105     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: To prospectively investigate the influence of 3-month neoadjuvant hormonal therapy (NHT) before brachytherapy (BT) for low-risk prostate cancer (PCa) on urinary function and health-related quality of life (HRQL).
METHODS: Between 2003 and 2008, 300 patients with PCa were treated with BT using (125)I stranded seeds, of whom 86 received 3-month NHT to downsize the prostate before treatment. Urinary complaints were measured on all occasions with the International Prostate Symptom Score (n = 134) and European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire PR25 (EORTC-QLQ-PR25 questionnaire; n = 118) and HRQL with the EORTC-QLQ-C30 (n = 120) questionnaire.
RESULTS: Post-BT, urinary function became worse over the first 6 weeks and then improved steadily, but did not return to baseline levels at 1 year. At baseline, the NHT group reported worse urinary function compared with the non-NHT group (P < .01). However, the post-BT improvement of urinary function was better in the NHT group at 3 months (P < .05). Global HRQL, physical, role and social functioning decreased over the first 3 months (P < .05) post-BT but returned to baseline levels within 1 year. Emotional function steadily improved over the 1-year follow-up period (P < .001). The NHT group reported better global HRQL, social and emotional functioning 1 year post-BT compared with baseline (P < 05). All results were adjusted for comorbidity. This is a single-center study with a follow-up of 1 year, thereby potentially limiting the general applicability of the results.
CONCLUSIONS: Three months of NHT before BT might positively influence urinary function and HRQL up to 1 year post-BT. Therefore, PCa patients should not be dissuaded from considering NHT followed by BT because of prostate size.
Authors:
Judith Evers; Nina Kupper; Dionne Kessing; Rob Davits; Antoine Engelen; Philip Poortmans; Floortje Mols
Related Documents :
18353375 - The impact of prostate size on urinary quality of life indexes following laparoscopic r...
9313535 - Benign prostatic hyperplasia in older men.
15090275 - The utility of transition zone index in predicting acute urinary morbidity after 125i p...
10636565 - Interstitial laser coagulation and transurethral needle ablation in the management of l...
23291675 - Evaluation of the feasibility and efficacy of autologous stem cell transplantation in e...
19633885 - Natural orifice surgery: initial us experience utilizing the stomaphyx device to reduce...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Urology     Volume:  76     ISSN:  1527-9995     ISO Abbreviation:  Urology     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-11-08     Completed Date:  2010-12-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0366151     Medline TA:  Urology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1150-6     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 Elsevier Inc. All rights reserved.
Affiliation:
Department of Urology,TweeSteden Hospital, Tilburg, The Netherlands. securologietilburg@tsz.nl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Androgen Antagonists / adverse effects,  therapeutic use*
Anilides / therapeutic use*
Antineoplastic Agents / therapeutic use*
Brachytherapy*
Combined Modality Therapy
Gonadotropin-Releasing Hormone / adverse effects,  agonists*
Humans
Iodine Radioisotopes / therapeutic use
Male
Middle Aged
Neoadjuvant Therapy
Nitriles / therapeutic use*
Prostatic Neoplasms / physiopathology,  therapy*
Quality of Life*
Tosyl Compounds / therapeutic use*
Urination / drug effects*
Chemical
Reg. No./Substance:
0/Androgen Antagonists; 0/Anilides; 0/Antineoplastic Agents; 0/Iodine Radioisotopes; 0/Nitriles; 0/Tosyl Compounds; 33515-09-2/Gonadotropin-Releasing Hormone; 90357-06-5/bicalutamide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Exophytic benign prostatic hyperplasia.
Next Document:  New use of foley catheter for exposing the urethral stump during vesicourethral anastomosis in lapar...